Following is the remainder of the literature that Dr. Goldstein supplied me
                 with. Remember, this was written for humans.

                 Polydox or PolyMVA
                 A trimeric palladium compound with properties of a ucleotide reductase. It
                 is a dark, almost reddish brown liquid.

                 Introduction
                 Polydox is he name given to a novel compound recently patented. The chemical
                 descrtion and some of the chemical properties are described in the patent and
                 will not be reviewed here. Biochemical investigations ow in progress under
                 the direction of Garnett-McKeen may indicate that this compound activates
                 ntracellular receptors.

                 Theoretically, this activation has a minimal or no measurable effect on
                 normal cells but drives to destruction cells with altered (maliginant)
                 genetic changes.

                 Currently, most cancer chemotherapeutics when used in terminal stages
                 diminish the quality of life while providing various degrees of remission.
                 It is believed that POLYDOX may encourage tumor remission with minimal effect
                 or deterioration of quality of life.

                 Description
                 POLYDOX, the United States name, or POLYMVA, a compound with approval for use
                 in Mexico, is a synthetic nucleotide reductase.

                 The inventor, Dr. Merrill Garnettt, discovered that lipoic acid as used in
                 the present formula is highly specific for transferring electron energy from
                 a normal metabolic hydrogen carrier to nucleic acids.

                 The science of molecular biology indicates altered DNA as a principle fctor
                 in malignant development. Altered genes produce abnormal protein substances.
                 A major factor in the success of POLYDOX has been to provide an electron
                 energy transfer mechanism from normal metabolic hydrogen carriers to nucleic
                 acids. Nucleic acids are the main constituent of DNA. POLYDOX induces
                 energy dependat conformational changes in DNA as a result of the reduced
                 state it induces in the nucleotides.

                 It is postulated that ras oncogenesis is related to famesyl transfer.
                 Blocking this transfer allows the normalized transfer of electron charges to
                 occur from the lipid part of the membrane. In addition to its energy
                 transfer properties, POLYDOX is an effective anti-oxidant.

                 Cancerous cells, cells wtih altered DNA, are characterized as unable to
                 produce adequate wter as a product of normal metabolism. POLYDOX stimulates
                 the production of intracellular water, thus driving the cell toward normalcy.

                 Indications

                 POLYDOX is indicated n conditions of abnormal rapid cell division. Extensive
                 (over three years) use by Dr. Falk, oncologist of Canada, found no effect on
                 the normally rapidly dividing cells such as hair, lung, ntestne, or marrow
                 cells. Patients with abnormally dividing cells were in many cases benefitted.

                 Non-malignant Uses

                 Anecdotal reoprts indicate unusual success in the treatment of non-malignant
                 conditions such as fibromatosis, psoriasis, Alxheimer's disease, and multiple
                 sclerosis. POLODOX is also efective in the treatment of herpes, strokes, and
                 hepatitis.

                 There is a demonstrated tonic effect which has een widely reported especially
                 in older patients who suffer from fatigue and loss of appetite. This tonic
                 effect of increased energy is postulated to be caused by the activation of
                 B12 and thiamin molecules whose effect has been potentiated by the
                 configuration of the new molecule. This report will not discuss the many
                 functions and uses of these vitamins except to say that they seem to be more
                 active in POLYDOX form. It is possible that some of the beneficial
                 neurological changes reported n multiple sclerosis, central nervous system
                 malignant tumors, and Alzheimer's are due to the active vitamns contaned in
                 POLYDOX.

                 There is some evidence that palladium may be an essential trace metal. It
                 appears that palladium has an effect on the structure of certan bioinorganics
                 and thus changes their function. Further research is being done by Metals in
                 Medicine and the work of R. Lampeka of Department of Chemistry, Kiev
                 University and H. Wanjek of the Institute of Inorganic Chemistry, Munich
                 University.

                 Uses in Malignant Conditions

                 POLYDOX was invented with the purpose of finding a non-toxic treatment of
                 cancer. The altered gene was nown as the proximate cause of malignant
                 transformations. The ucleotides were identified as the b asic olecular
                 structures which controlled cell division and replication. Enzymes were
                 known to effet DNA repair and thus Dr. M. Garnett focused his research on
                 nucleotide reductases with the result of the development of POLYDOX.

                 The concept of repairing the altered gene as a treatment for cancer by using
                 semisynthetic compound is a major departure from the current concept of
                 destruction. The most dramatic responses were noted with BRAIN TUMORS.
                 Rapid success has been documented in cases of Glioblastomas. Even in the
                 late stages with extensive symptoms of partial paralysis, memory changes, and
                 ambulatory abnormalities, there was a quick return to normal functions.

                 Lung cancers, especially bronchogenic carcinomas, are notoriously difficult
                 to treat. POLYDOX use has substantially increased life span. Excess pleural
                 fluid is a complication, but can be reduced by reducing the dose of POLYDOX.

                 Ovarian cancers respond well to oral use of POLYDOX. Long term success in
                 this cancer and others is related to long term use of POLYDOX.

                 Breast cancers, whether they are hormone sensitive or not, seem to respond to
                 POLYDOX. Late stages with extensive bone metastasis have reported resolution
                 of the bone loss and reduction of pain. Megace, an antiestrogen, augments
                 the benefit.

                 Symptom Relief

                 Any cancer patient who has suffered pain, anorexia or weight loss may benefit
                 from a 30 day trial. Most cancer patients report improved appetite and
                 weight gan within the first few days of beginning POLYDOX. The question of
                 how POLYDOX erduces pain in cancer requires more invetigation. One theory
                 suggest that as the tumor cells are destroyed, the smaller mass reduces
                 pressure caused pain.

                 As an Adjuvant

                 The original work on humans in Canada proved that POLYDOX was very safe. In
                 over two years of use, it produced no reactions. Its main use was an
                 adjuvant. It was used in Canada by an oncologist, Dr. Falk

                 As an Adjuvant

                 The original work on humans in Canada proved that POLYDOX was very safe.  In
                 over two years of use, it produced no reactions.  Its main use was an
                 adjuvant.  It was used in Canada by an oncologist, Dr. Falk, usually in
                 conduction with standard chemotherapy.  He reported benefits using this
                 combination in the majority of patients.  The benefits he reported included
                 pain reduction or pain control, increased energy, improved appetite and
                 weight gain.  Some patients are still using low doses of POLYDOX and have no
                 apparent signs of cancer after two or three years of use.

                 Radiotherapy

                 The strong antioxidant effects of POLYDOX are probably responsible for the
                 increased benefit of radiation treatments.  It is postulated that (1) POLYDOX
                 protects surrounding tissues, thereby causing less postirradiation damage (2)
                 POLYDOX sensitizes the malignant cell, making it more responsive to lower
                 doses of malignant cell, making it more responsive to lower doses of
                 radiation.  These effects require more controlled studies.

                 TOXICITY STUDIES

                 Animal studies and the studies in Canada prove the very safe nature of
                 POLYDOX.  Toxicity studies were performed which et the standards of the FDA.
                 They proved there was no toxicity in the doses tested.  Extensive intravenous
                 and oral toxicity studies by testing agent Pharmakon USA, PO Box 600,
                 Waverly, PA, reported:

                 "Based upon the results from the Acute Intravenous Toxicity Study in mice,
                 the test article synthetic Reductase 25mg/ml is considered to be non-toxic
                 when administered as an intravenous injection of 15.0 ml/kg."

                 "Based upon the results from the Acute Oral Toxicity Study in Mice (14 day),
                 the estimated acute oral LD50 for combined sexes for the Synthetic Reductase
                 (25mg/ml) is determined to be greater than 5000 mg/kg."

                 Mitogen tests are routinely performed by using Ames/Salmonella Assay.  "The
                 results of synthetic DNA reductase were negative."

                 There is also a To Whom it May Concern letter dated May 1998 from a NYC vet
                 who was treating a 10 yr. old neutered male Siamese who was diagnosed with
                 lymposarcoma, soft tissue on bridge of nose.

                 The owner decided instead of conventional therapies to treat the cat solely
                 with POLYMVA.  After two months of oral POLYMVA the cat has no visible mass
                 on his nose.



                 Marla
                 Country & Kiska

 Dear Bobby,

We got ours directly from Poly distributor. The
contact person is Tim Maston 1-800-960-6760,
(cell)619-571-1096

Advanced Medical Research Center
539 Telegraph Cny Rd PMB 281
Chula Vista CA 91910
619-656-1980

The site to go is the poly survivor's URL. AMRC do
give out free bottle of Clodronate (sp)/Bonefos for
free with Poly order if requesed. The price is pretty
standardlized nowadays. $360 per 240 cc. That lasts 10
days in Dago's case (he weighed 50 lbs then). When buy
10 at once, they drop to $330 per bottle.

There are other souces that may be cheaper, such as
from Mexico, but the chance of conterfeit is not worth
the risk. My only caution advice to any protential
users is to adhere to the recommended dosage to get
Poly's benefit. Because this product is so "young",
the makers and users are in experimental state, the
dose changed from the product's inception of 4 cc per
day for doggies to body weight dependancy.

There is a live doggie case on Poly discussion group
in yahoo. Benson has brain tumor and Poly shrunk the
tumor 15% (?) in 25 days.



http://www.polymvasurvivors.com/